TSCAN THERAPEUTICS INC. (NASDAQ: TSCN) SHARES ARE UP 0.9% IN THURSDAY SESSION

Trending News ☀️

TSCAN ($NASDAQ:TCRX) Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of drugs for the treatment of cancer. Telomerase is an enzyme that plays a role in the maintenance of telomeres, which are the protective structures at the end of chromosomes.

Price History

The company’s stock opened at $3.2 and closed at $3.3, up by 3.7% from prior closing price of 3.2.

VI Analysis

TSCAN THERAPEUTICS is a low risk investment in terms of financial and business aspects. The company’s fundamentals reflect its long term potential, and the company’s VI app makes analyzing the company’s potential risks simple. However, it is important to note that potential risks should be considered when making any investment decision.

VI Peers

TScan Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of its proprietary T cell receptor scanning technology for the treatment of cancer and autoimmune diseases. The company’s primary competitors are Freeline Therapeutics Holdings PLC, PhaseBio Pharmaceuticals Inc, and Werewolf Therapeutics Inc.

– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

Freeline Therapeutics Holdings PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for chronic liver diseases. The company has a market cap of $42.89 million and a return on equity of -1.18%. Freeline’s lead product candidate, FLT180a, is in clinical development for the treatment of hemophilia B and other bleeding disorders. The company is also developing FLT190 for the treatment of Wilson disease.

– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)

Bio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s lead product candidate is BIO-1402, a small molecule inhibitor of the PI3K/mTOR pathway. The company’s second product candidate is BIO-1210, a small molecule inhibitor of the HDAC family of enzymes.

– Werewolf Therapeutics Inc ($NASDAQ:HOWL)

Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product candidate, WTX-124, is a monoclonal antibody that targets the protein CD47, which is overexpressed on the surface of cancer cells and inhibits the body’s natural immune response to cancer. Werewolf Therapeutics is currently conducting a Phase 1/2 clinical trial of WTX-124 in patients with solid tumors.

The company’s market cap as of 2022 is 112.8M. The company has a Return on Equity of -28.8%.

Summary

TSCAN Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel cancer therapies. The company’s lead product candidate is tivozanib, which is in Phase III clinical trials for the treatment of renal cell carcinoma. The stock has been volatile, but has trended up over the last year. The company is not yet profitable, but has shown strong revenue growth. Investors may be interested in TSCAN as a potential high-growth stock. The company’s lead product candidate has shown promise in clinical trials and could be a potential blockbuster drug if approved.

However, the stock is risky and investors should do their own due diligence before investing.